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The challenge of genome medicine is not to make a significant move into the clinic over the next
five years. The floodgates of genomic research have been opened, and the hopes are that the
rising tide will spill over into medical practice in the form of diagnostic tests, risk assessment
tools and therapeutics. The ability to perform genome-wide analyses using several different
approaches has already provided tantalizing new clues to disease causation and therapeutic
targets. Companies have sprung up to use these new technologies to provide information to
individuals about predicted health and disease, and about behavioral traits. As exciting as these
prospects are, it is far too soon to promise clinically useful information from genomic analyses.
We have far to go to assure basic levels of analytical validity or clinical validity of the diagnostic or
predictive tools on offer, and to determine their clinical utility in the medical context.
The main issue currently facing the translation of genomics
research into clinical practice is that it will require researchers,
clinicians and patients to make a significant conceptual shift
from Mendelian ways of thinking to a post-Mendelian world.
Ironically, in this new world, genes have a lesser role as we
study ever more complex diseases and traits and begin to
understand the interplay of gene-gene and gene-environment
interactions and epigenetics. It is nearly 100 years since
Wilhelm Johanssen first coined the word ‘gene’ and posited
a relationship between genotype and phenotype. Since then,
we have learned that there is a lot more to this relationship
than we initially envisaged.
Currently, genome-wide association studies increasingly
identify the contribution of multiple genetic loci to pheno-
types by providing clues as to the biological pathways and
interactions involved. However, we are far from knowing
how the results of these studies are clinically relevant. As a
result, we also do not yet know how to explain these results
in a meaningful way to patients.
The shift to post-Mendelian genomics will require different
ways of thinking about the validation, interpretation and
explanation of genomic studies, especially with respect to
their application to clinical practice. Recent comprehensive,
large-scale studies such as that by the Wellcome Trust Case
Control Consortium [1] have been very valuable at
connecting biochemical pathways with diseases, such as age-
related macular degeneration [2]. The challenge of estab-
lishing and replicating genotype-phenotype associations
remains, however [3,4], leading to cautions about how to
design and interpret genome-wide association studies [5-7].
Validation of genotype-phenotype associations is of course
critical to the successful translation of genomic data to clinical
practice. Basic issues of analytical validity must be addressed,
especially as new analytical platforms are developed, such as
array comparative genomic hybridization to determine copy-
number variation. The biases and reliability of these relatively
new methods is still in flux [8-10] and minimum standards of
analytical validity must be established in order to use these
platforms for clinical application [11,12].
The potential for rigorous statistical analysis to minimize
false positive results has been widely discussed [5-7], as well
as the need for sound study design, including care in subject
selection and controlling for population substructure.
However, even after a genotype-phenotype association has
been identified and replicated, establishing clinical validity
and developing a useful clinical diagnostic test requires
much more work. The fact that the demonstration of an
association is not the same as finding a causal variant, much
less the majority of causal variants, is probably not well
understood by clinicians and the general public. Personal
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genome ‘covers’ health conditions of interest, such as
Alzheimer’s disease or breast cancer, but this idea is
misleading. For example, the Navigenics Health Compass
scans an individual’s genome at 1.8 million loci for variants
that are associated with 18 relatively common conditions
and for which the association has been published in a peer-
reviewed journal and the finding replicated at least once
[13]. However, although the Health Compass claims to cover
breast cancer, the test does not examine the BRCA1 and
BRCA2 genes at the sequence level, which is something a
patient with hereditary breast and ovarian cancer in their
family would require and expect of a truly personalized
genetic risk assessment.
The 23andme website [14] claims that “23andMe can help
you discover how your genes may affect your chances of
developing various diseases and conditions, as well as traits
such as athletic ability”. However, this statement is in
contrast to those of genome researchers [2,15], who have
stressed that the contribution of single genes is often small,
commonly with odds ratios of less than 1.5, and thus perhaps
clinically insignificant [16]. How to interpret the clinical
significance of genetic contributions when some loci
associated with traits and diseases contain no known genes
is even more unclear.
How to interpret the effects of multiple genes associated with
a particular condition poses a major challenge to clinical
practitioners and patients. For example, analyses of Craig
Venter’s  DRD4 and  DRD3 genes (associated with ‘novelty
seeking’) indicated that at one locus his genotype indicated
that he had a variant not associated with higher novelty-
seeking scores but at other loci his alleles were associated
with higher novelty-seeking scores [17]. Given the multi-
factorial nature of most traits, it still needs to be worked out
how the growing amount of genomic information should be
interpreted and explained when aggregated.
Fundamentally, the idea that genomic analysis provides only
part of a very complex picture must be conveyed. In the
Mendelian era, almost by definition, diseases were more
obviously delineated because they were clearly inherited and
the role of epigenetic and environmental factors did not need
to be addressed. In the post-Mendelian world, the complexity
of, and need for, defining and measuring phenotypes and
environmental factors is only now beginning to be appreciated
by the research community, but is not well understood by
prospective patients and their health care providers.
Over the next five years, the challenge for genome medicine
is thus not to make a significant move into the clinic.
Although this is a desirable goal, it would be premature.
Scientists, clinicians and the general public first need to
change their way of thinking about the role of genes and
genomes in everyday health.
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